Wall Street Journal -- Boston Scientific showed that its $30,000 devices that slow heart deterioration, called cardiac resynchronization therapy defibrillators, produced clinical benefit in a 1,820-patient clinical trial, according to results published in today’s New England Journal of Medicine.
